A detailed history of Rhumbline Advisers transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 87,208 shares of FULC stock, worth $396,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,208
Previous 91,432 4.62%
Holding current value
$396,796
Previous $566,000 45.05%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.18 - $9.74 $13,432 - $41,141
-4,224 Reduced 4.62%
87,208 $311,000
Q2 2024

Aug 01, 2024

BUY
$5.98 - $9.31 $536,854 - $835,805
89,775 Added 5417.92%
91,432 $566,000
Q3 2023

Nov 09, 2023

SELL
$3.25 - $6.08 $10,185 - $19,054
-3,134 Reduced 65.41%
1,657 $7,000
Q2 2023

Aug 08, 2023

SELL
$2.26 - $3.8 $159,818 - $268,720
-70,716 Reduced 93.65%
4,791 $15,000
Q1 2023

May 11, 2023

BUY
$2.83 - $13.99 $44,648 - $220,720
15,777 Added 26.41%
75,507 $215,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $45,105 - $75,175
9,003 Added 17.75%
59,730 $435,000
Q3 2022

Nov 10, 2022

BUY
$4.92 - $9.1 $15,744 - $29,120
3,200 Added 6.73%
50,727 $410,000
Q2 2022

Aug 11, 2022

BUY
$4.2 - $24.0 $56,330 - $321,888
13,412 Added 39.31%
47,527 $233,000
Q1 2022

May 12, 2022

BUY
$9.96 - $23.65 $23,983 - $56,949
2,408 Added 7.59%
34,115 $807,000
Q4 2021

Feb 10, 2022

BUY
$14.0 - $28.44 $21,112 - $42,887
1,508 Added 4.99%
31,707 $561,000
Q3 2021

Nov 12, 2021

BUY
$7.28 - $30.97 $56,230 - $239,212
7,724 Added 34.37%
30,199 $852,000
Q2 2021

Aug 05, 2021

BUY
$8.09 - $12.0 $81,870 - $121,440
10,120 Added 81.91%
22,475 $236,000
Q1 2021

May 06, 2021

BUY
$10.94 - $15.32 $5,360 - $7,506
490 Added 4.13%
12,355 $146,000
Q4 2020

Feb 10, 2021

BUY
$7.84 - $13.4 $9,800 - $16,750
1,250 Added 11.78%
11,865 $139,000
Q3 2020

Nov 12, 2020

SELL
$7.22 - $20.7 $15,234 - $43,677
-2,110 Reduced 16.58%
10,615 $84,000
Q2 2020

Aug 13, 2020

BUY
$9.11 - $22.06 $115,924 - $280,713
12,725 New
12,725 $233,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.